Form 4: Neumora Therapeutics President's Stock Options Repriced to Boost Executive Incentive

Neumora Therapeutics, Inc. (NMRA) has repriced stock options for its President, Joshua Pinto, significantly lowering the exercise price from $1.69 to $0.72 per share, following stockholder approval on May 28, 2025.

Summary

• Joshua Pinto, President of Neumora Therapeutics, Inc. (NMRA), had 4,734,428 stock options repriced on May 28, 2025.
• The exercise price for these options was reduced from $1.69 per share to $0.72 per share.
• The repricing was approved by the Issuer's stockholders on May 28, 2025.
• The repricing is contingent on Mr. Pinto remaining in service to Neumora Therapeutics through August 13, 2026.
• Various tranches of these options have different vesting schedules, with some vesting monthly over three or four years from their respective commencement dates, and one performance-based option vesting upon stock price milestones.

Sentiment

Score: 4

Explanation: The sentiment is mixed to slightly negative from a shareholder perspective. While it re-incentivizes management, the need for repricing suggests past stock underperformance. The significant reduction in exercise price could lead to future dilution, which is generally negative for existing shareholders, despite the positive aspect of executive retention.

Positives

• The repricing significantly lowers the exercise price for Joshua Pinto's stock options, enhancing their intrinsic value and re-incentivizing the executive.
• Stockholder approval of the repricing indicates alignment between the company's board and its shareholders regarding executive compensation and retention strategies.

Negatives

• The need for a stock option repricing often signals that the company's stock price has underperformed, making original options underwater and less effective as an incentive.
• A lower exercise price could lead to increased dilution for existing shareholders if the stock price recovers and these options are exercised, as more shares may be issued at a lower cost.

Risks

• Potential for increased share count and dilution if the repriced options are exercised, impacting existing shareholder value.
• Risk of management retention issues if the condition for the repricing (Joshua Pinto remaining in service through August 13, 2026) is not met.
• The repricing may be perceived negatively by some investors as a sign of past stock underperformance or a lack of confidence in the original compensation structure.

Future Outlook

The repricing of stock options for the President is intended to re-incentivize key management, suggesting a focus on future performance and retention. The condition that the executive remains in service through August 2026 indicates a long-term commitment to the company's strategic objectives.

Management Comments

• "On May 28, 2025, the Issuer's stockholders approved the repricing of the option. As further described in footnote 9, all other terms of the option remain unchanged."
• "On May 28, 2025, the Issuer's stockholders approved an option repricing at an exercise price of $0.72 per share (the 'Repricing') of the outstanding stock options held by members of the Board, certain employees and other service providers. The Repricing is subject to the Reporting Person remaining in service to the Issuer through August 13, 2026."

Industry Context

Stock option repricing is a common practice in the biotechnology and pharmaceutical industries, particularly for early-stage or growth companies, when stock prices have declined significantly, rendering existing options underwater. This mechanism is often used to retain and motivate key executives and employees by restoring the incentive value of their equity awards, aligning their interests with future company growth.

Comparison to Industry Standards

• Option repricing is a recognized, albeit sometimes controversial, tool for executive retention and motivation in industries with volatile stock performance, such as biotech.
• The approval by stockholders for this repricing aligns with best practices for corporate governance, ensuring transparency and accountability for significant compensation changes.
• While specific comparable companies or projects are not mentioned in the filing, such repricings are typically observed in companies where the stock price has fallen below previous grant prices, similar to instances seen with other emerging biotech firms facing clinical trial risks or market headwinds.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential for increased dilution if the repriced options are exercised, but also potential for improved executive motivation leading to better future performance.
• Employees (specifically Joshua Pinto): Significantly improved incentive value of their stock options, enhancing retention and motivation.
• Creditors: No direct impact mentioned.

Next Steps

• Joshua Pinto is expected to continue his service to Neumora Therapeutics, Inc. through August 13, 2026, to fulfill the condition of the repricing.
• The repriced stock options will continue to vest according to their respective schedules, contingent on continued service and, for some, achievement of performance milestones.

Key Dates

Recommendation

Keywords

Neumora Therapeutics, NMRA, Stock Options, Repricing, Executive Compensation, Form 4, Insider Transaction, Corporate Governance, Biotechnology, Pharmaceuticals